{"id":14673,"date":"2025-10-09T11:57:23","date_gmt":"2025-10-09T06:27:23","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=14673"},"modified":"2025-10-09T12:57:28","modified_gmt":"2025-10-09T07:27:28","slug":"stock-to-buy-today-october-9-2025","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/stock-to-buy-today-october-9-2025\/","title":{"rendered":"Stock to Buy Today: October 9, 2025"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]Benchmark indices Sensex<\/a> and Nifty 50<\/a> declined on Wednesday, snapping a four-day rally due to selling pressure in major stocks like Reliance Industries<\/a> and HDFC Bank<\/a>. The Sensex closed 153.09 points lower (0.19%) at 81,773.66, while the Nifty 50 slipped 62.15 points (0.25%) to 25,046.15.<\/p>\n

Analysts attributed the decline to profit-taking in auto<\/a>, banking<\/a>, and real estate<\/a> sectors, coupled with mixed earnings results and cautious investor sentiment ahead of the Q2 earnings season. While IT stocks<\/a> remained relatively stable, weak global cues and subdued domestic momentum weighed on overall market sentiment.<\/p>\n

Amidst this cautious environment, Abbott India Ltd. stands out as a stock worth tracking for its strong fundamentals, innovative product launches, and consistent long-term performance.<\/p>\n

<\/span>Abbott India Ltd. [NSE: ABBOTINDIA]<\/strong><\/span><\/h2>\n

Abbott India<\/a>, a leading pharmaceutical and healthcare company, has been making headlines with the launch of its dual-chamber leadless pacemaker system\u2014a major leap in cardiac care technology. The AVEIR DR system allows wireless synchronisation between two miniature pacemakers implanted directly in the heart, significantly reducing procedural risks and improving recovery times.<\/p>\n

This innovation marks a breakthrough in cardiac rhythm management, offering patients safer, minimally invasive treatment options. Despite a moderate share price response following the announcement, the long-term implications for Abbott\u2019s medical devices portfolio remain highly positive.<\/p>\n

From a market standpoint, Abbott India has outperformed both the Nifty and Nifty Pharma<\/a> indices over the past year, rising around 8.8% year-on-year, while broader benchmarks declined. The company\u2019s steady growth, healthy balance sheet, and consistent dividend payouts underscore its reputation as a stable defensive bet in volatile markets.<\/p>\n

For investors, Abbott\u2019s blend of strong brand equity, steady earnings, and R&D-driven innovation makes it a resilient choice for medium to long-term portfolios, especially within the healthcare and medical technology segments.<\/p>\n

<\/span>Key Metrics<\/strong><\/span><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Metric<\/strong><\/td>\nDetails<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Closing Price (as of Oct 8, 2025)<\/strong><\/td>\n\u20b929,925.00<\/td>\n<\/tr>\n
52-Week Range<\/strong><\/td>\n\u20b925,325 \u2013 \u20b937,000<\/td>\n<\/tr>\n
Market Cap<\/strong><\/td>\n\u20b963.29KCr<\/td>\n<\/tr>\n
P\/E Ratio<\/strong><\/td>\n43.58<\/td>\n<\/tr>\n
Dividend Yield<\/strong><\/td>\n1.59%<\/td>\n<\/tr>\n
Average Trading Volume<\/strong><\/td>\n8.83K<\/td>\n<\/tr>\n
Company Type<\/strong><\/td>\nMid-cap Stock<\/a><\/td>\n<\/tr>\n
Beta<\/strong><\/td>\n0.43<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Why Abbott India is a Stock to Watch<\/strong><\/span><\/h2>\n